Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's CDSCO Orders Improved State-Level Drug Inspections

This article was originally published in PharmAsia News

Executive Summary

India's Central Drugs Standard Control Organization has ordered state regulators to tighten their inspection systems, report more quickly and improve procedures for the qualification of inspectors.

India's Central Drugs Standard Control Organization has ordered state regulators to tighten their inspection systems, report more quickly and improve procedures for the qualification of inspectors. The CDSCO order is an apparent attempt to bolster international confidence in the quality of India's pharmaceutical products. The agency letter listed several practices for the regulators to follow, down to successful inspections of production facilities. (Click here for more - a subscription may be required)

"India Outlines Plan To Boost Inspections Of Drug Facilities" - Wall Street Journal (8/12/2014)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel